Chemical synthesis of exochelins

Details Chemical synthesis of exochelins Chemical synthesis of exochelins

1999-03-05

2002-01-01

Kifle, Bruck (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

C540S526000

Reexamination Certificate

active

06335443

ABSTRACT:

BACKGROUND OF THE INVENTION
The present application expressly incorporates by reference U.S. Ser. No. 08/383,180, now U.S. Pat. No. 5,721,209, U.S. Ser. No. 08/796,791, now U.S. Pat. No. 5,786,326, U.S. Ser. No. 08/882,122; and U.S. Ser. No. 08/960,714, all to Horwitz, et al., all of which are subject to an exclusive license or assignment to the same assignee as this application.
The present invention relates to a heretofore undisclosed process for the synthetic generation of high affinity, iron binding compounds known as Exochelins, and more particularly, to a synthetic process for making Exochelins and to modifications to these newly synthesized compounds to vary their physiological properties, including applications of these newly synthesized and utile compounds for diagnosing and treating disease in mammals.
The above referenced U.S. Patents and applications have shown that exochelins have unique physiological benefits. For example, in acute myocardial infarction, cardiac tissue is damaged by two sequential events, hypoxia in the ischemic phase and oxidative damage in the reperfusion phase. Myocardium damaged in the ischemic phase can be salvaged by reintroduction of blood into the ischemic area. However, reperfusion can result in injury to the reperfused tissue as a result of an inflammatory response caused by the migration of leucocytes into the tissue and the production of reactive oxygen species. One of the most reactive species is the hydroxyl radical (—OH) which is generated in the presence of iron, and which often results in cell death or related oxidative tissue damage.
Prevention of the formation of (—OH) prevents lethal cell damage by several mechanisms. It is well known that the formation of (—OH) is dependent on the presence of free iron, and that iron chelators will prevent reperfusion injury. For example, the iron chelator deferoxamine, when administered prior to reperfusion, prevents injury and reduces myocardial infarct size during coronary artery occlusion and reperfusion. However, reperfusion injury occurs rapidly after the reestablishment of blood flow to the ischemic myocardium.
The formation of the (—OH) radical is dependent on the presence of free iron and iron chelators can scavenge the free iron and thus render the iron unavailable to catalyze the hydroxyl radical formation. However, prior known chelating means either do not prevent (—OH) production by the Fenton Reaction (i.e., EDTA), or enter the cells too slowly (i.e., desferrioxamine). As a result, sufficient quantities of the chelating agent are not available to act rapidly enough to chelate enough iron to prevent the formation of (—OH) and cell damage and destruction which results.
Desferrioxamine has been demonstrated to be effective if administered prior to occurrence of the myocardial infarct but to be ineffective if administered at or after the onset of reperfusion. Similar injury to heart tissue can occur as a result of heart bypass procedures, such as during open heart surgery, or to other body organs when they are deprived of oxygenated blood as a result of surgery or injury. Thus, iron scavenging chelators are clearly needed to prevent oxidative tissue damage.
Prior to the discoveries of Horwitz, et al., compounds referred to as Exochelins had been briefly described, and their general function in the growth of mycobacteria was likewise discussed by Macham, Ratledge and Barclay at the University of Hull in England (MACHAM, L. P., RATLEDGE, C. and NOCTON J. C., “Extracellular Iron Acquisition by Mycobacteria: Role of the Exochelins and Evidence Against the Participation of Mycobactin”,
Infection and Immunity
, December 1975, pp.1242-1251, Vol. 12, No.6; BARCLAY, R. and RATLEDGE, C., “Mycobactins and Exochelins of
Mycobacterium tuberculosis, M. bovis, M. africanum
and Other Related Species”,
Journal of General Microbiology,
1988, pp.134, 771-776; MACHAM, L. P. and RATLEDGE, C.,
Journal of General Microbiology,
1975, pp. 89, 379-382).
Macham identified the existence of a substance found in the extracellular fluid, which he referred to as ‘exochelin’. Macham further described the materials he referred to as exochelins as water and chloroform soluble compounds having the ability to chelate free iron. Macham, et al., did not isolate or purify the compounds, merely characterizing them as penta- or hexapeptide, with molecular weights in the range of 750 to 800, inter alia.
According to Macham's work, his exochelins have similarities to mycobactin—which is located in the cell wall and functions to transmit iron to the interior of the cell. However, unlike mycobactin, a lipophilic, water insoluble molecule which is unable to diffuse into, and assimilate free iron from the extracellular environment, Exochelin functions at physiological pH to sequester iron from other iron bearing compounds in the serum. Also, depending on the bacterial source of the compounds, Macham, et al. disclosed that his molecules may also include salicylic acid or beta-alanine.
Barclay et al. (Ibid.)likewise described the production of compounds he called exochelins from twenty-two different strains of
M. tuberculosis
and related species. However, neither these, nor any other known prior investigators, determined the specific structure of those compounds, or identified any application for the same outside of their function as a transport medium for iron to mycobactin located in the cell wall.
In sum, Macham et al. recognized that after sequestering iron from, for example, ferritin or transferrin (and the like iron bearing compounds found in the serum) his compounds present the iron in a form that can be transferred to mycobactin, while Barclay et al. described production of his compounds from known mycobacterial strains without precisely elucidating their structure.
The total synthesis of a related compound, Mycobactin S2, was reported by Maurer and Miller in 1983 (MAUER, P. J. and MILLER, M. J. “Total Synthesis of a Mycobactin: Mycobactin S2”, 1983
, J. Am. Chem. Soc
., pp. 240-245, Vol. 105). Mauer et al. successfully prepared 29 milligrams of a Mycobactin utilizing a complex, multi-step synthetic pathway. Mycobactin S2, however, is significantly different from the target molecule according to the synthesis of the present invention. Likewise, Exochelin synthesis remains unreported to date.
The following references provide teachings relevant to the synthesis according to the present invention:
MAUER, P. J. and MILLER, M. J., 1982
, J. Am. Chem. Soc.,
104, 3096;
FARKAS, L. et al., 1967
, Tetrahedron,
23, 741;
SCHNIEPP, L. E. and GELLER, H. H., 1946
, J.Am. Chem. Soc.,
68, 1646;
GAUDRY, R., 1948
, Can. J. Res. Sect. B,
26, 387;
DREYFUSS, P., 1974
, J. Med. Chem.,
17(2),252;
BERLINGUET, L. and GAUDRY, R., 1952
, J. Biol. Chem.,
198, 765;
BODANSZKY, M., et al., 1978
, J. Med. Chem.,
21(10),1030;
MAURER, P. J. and MILLER, M. J. 1981
, J. Org. Chem. Soc.,
46(13), 2835;
BIRNBAUM, S. M., LEVINTOW, L. KINGSLEY, R. B. and GREENSTEIN, J. P., 1952
, J. Biol. Chem.,
194, 455;
COREY, E. J. and VANKATESWARLU, A., 1972
, J. Am. Chem. Soc.,
94, 6190;
SIEBER, P., 1977
, Helv. Chim. Acta,
60, 2711 (b);
GERLACH, H., 1977
, Helv. Chim. Acta,
60, 3039;
MITSUNOBU, O., 1981
, Synthesis,
1981, 1.
Horwitz, et al., have discovered the currently accepted structural nature of exochelins, and patented uses of the same as novel iron chelators to inhibit the iron mediated oxidant injury which occurs during reperfusion, and have applications pending to other hydroxyl radical related insults to living tissues, including cancer, arteriosclerosis, organ preservation and vessel occlusion following angioplasty.
Likewise, the synthesis of related compounds strongly suggests the medical need for, and the production of synthetic versions of such important and needed compounds. See, for example, HU, J. and MILLER, M. J., “Total Synthesis of a Mycobactin S, a Siderophore and Growth Promoter of
Mycobacterium Smegmatis
, and Determination of its Growth Inhibitory Activity against
Mycobacterium tuberculosis”,
1997, pp.3462-3468, J. Chem.

Affiliated with

Also associated with

Rating

Chemical synthesis of exochelins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemical synthesis of exochelins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical synthesis of exochelins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2824761